Halozyme Therapeutics, Inc. Financials

Market Capitalization $6.65 Billion as of July 1, 2025

Valuations Metrics as of Jul. 4, 2025

Trailing PE	14.36
Forward PE	11.16
Price to Sales TTM	$6.14
Price to Book MRQ	$13.79
Enterprise to Revenue	6.64
Enterprise to EBITDA	10.69

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	44.76%
Operating Margin	53.44%
Return on Assets TTM	18.50%
Return on Equity TTM	147.06%

Income Statement

Revenue TTM	$1,084,306,048
Revenue per Share TTM	$8.61
Quarterly Revenue Growth	35.20%
Gross Profit TTM	$825,883,008
EBITDA	$679,023,000
Net Income to Common TTM	$485,363,008
Diluted EPS TTM	$3.76
Quarterly Earnings Growth YoY	53.70%

Balance Sheet

Total Cash MRQ	$747,921,984
Total Cash per Share MRQ	$6.07
Total Debt MRQ	$
Total Debt to Equity MRQ	318.67
Current Ratio MRQ	8.39
Book Value per Share MRQ	$3.92

Cash Flow

Operating Cash Flow TTM	$503,857,984
Levered Free Cash Flow TTM	$402,429,888

HALO Stock Info as of Jul. 4, 2025

Stock Statistics

Shares Outstanding	123,138,000
Float Shares	121,828,603
Avg 10 Volume	4,352,740
Avg 30 Volume	None
Shares Short	11,065,499
Short Ratio	4.10
Short % of Shares	12.29%
% Held by Insiders	1.11%
% Held by Institutions	101.97%

Stock Price Summary

Beta	1.19
Fifty Two Week Low	$42.01
Fifty Two Week High	$70.51
Fifty Two Week Change	4.52%
Day 50 MA	$55.82
Day 200 MA	$55.52

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date